Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alofanib in metastatic gastric cancer
NCT04071184Phase 1Unknown
- Sponsor
- Russian Pharmaceutical Technologies LLC
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alofanib in gastric cancer (GC), sponsored by Russian Pharmaceutical Technologies LLC. Primary endpoint: Maximum Tolerated Dose or Recommended Phase 2 Dose at 6 months. Status: unknown.
02
Drugs
alofanib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04071184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071184.